Study Information
Status: Active, Recruiting
Study Details
View study details on clinicaltrials.gov.
Locations
East Bay, Santa Rosa, Greater Sacramento Valley, San Francisco, Modesto, Palo Alto/Santa Cruz, San Mateo, Solano/Vallejo
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Lung Cancer (LUNG-MAP Sub-Study)
Principal Investigator
Related Studies
The Impact of Smoking, Comorbidities, and Race/Ethnicity on COVID-19 Infection and Disease Severity
Using EHR from a large healthcare system in Northern CA, we will study the impact of smoking, comorbidities, race on COVID-19 infection and disease severity.
Investigator: Jiang Li, Ph.D., MPH